MedTrace Logo

Financial Toxicity in Patients With Early-stage Breast Cancer

NCT07354165 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 864

Last updated 2026-01-21

No results posted yet for this study

Summary

Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for early-stage breast cancer patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.

Conditions

Interventions

OTHER

Questionnaires

The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16). EORTC QLQ-C30, EORTC QLQ-BR42 and HADS questionnaires are currently used in clinical practice

Sponsors & Collaborators

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Maria Carmela Piccirillo, MD · National Cancer Institute, Naples

  • Martina Pagliuca, MD · Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2030-09-30
Completion
2034-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07354165 on ClinicalTrials.gov